Abstracts tagged "treatment and tocilizumab"

Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ariella Kelman⁶, Sophie Dimonaco⁷ and Nina Mitchell⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Genentech, South San Francisco, CA, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…
Abstract Number: 2364 • 2013 ACR/ARHP Annual Meeting
Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naïve Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 24 Weeks Of Follow-Up
Soichiro Tsuji¹, Akiko Yura², Michihito Katayama¹, Satoru Teshigawara¹, Maiko Yoshimura¹, Eriko Tanaka¹, Yoshinori Harada², Yoshinori Katada², Masato Matsushita³, Shiro Ohshima⁴, Jun Hashimoto¹ and Yukihiko Saeki⁴, ¹Dept of Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ²Dept of Allergology, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ³Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Dept of Clinical Research, Clinical Research,Osaka-Minami Medical Center, Kawachinagano City, Japan
Background/Purpose: , :Procalcitonin(PCT) is a useful marker of infection. PCT-mRNA increases expression from peripheral blood mononuclear cells by stimulation of a pro inflammatory cytokine, IL-6…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 1662 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury
Kristine Kuhn¹, Hiroyuki Miyoshi², Nicholas A. Manieri², Nicole P. Malvin², Vinieth Bijanki², Paul Allen² and Thaddeus S. Stappenbeck², ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO, ²Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Inhibition of IL-6 is used for treatment of rheumatoid arthritis and now being investigated as biologic therapy for a wide variety of autoimmune conditions,…
Abstract Number: 1640 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Mark C. Genovese¹, Anthony Sebba², Andrea Rubbert-Roth³, Juan José Scali⁴, Rieke Alten⁵, Joel M. Kremer⁶, Laura Pitts⁷, Emma Vernon⁷ and Ronald F. van Vollenhoven⁸, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²University of South Florida, Tampa, FL, ³University of Cologne, Cologne, Germany, ⁴Durand University Hospital, Buenos Aires, Argentina, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Roche, Welwyn Garden City, United Kingdom, ⁸Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ)—an IL-6 receptor inhibitor—has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving physical function in rheumatoid arthritis (RA) patients (pts). This…
Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Marie Kostine¹, Thomas Barnetche², Elodie Ardouin³, Marlene Joly⁴, Emilie Rabois⁵, Baptiste Glace Sr.⁶, Delphine Nigon⁷, Thierry Schaeverbeke⁸ and Christophe Richez⁹, ¹Rheumatology, CHU Pellegrin, Bordeaux, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Limoges University Hospital, Limoges, France, ⁴Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Purpan, Toulouse, France, ⁸Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁹Hôpital Pellegrin and Université Victor Segalen Bordeaux, France
Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…
Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
HC Leffers¹, Mikkel Østergaard¹, Bente Glintborg², Niels Steen Krogh³, Ulrik Tarp⁴, Tove Lorenzen⁵, Annette Hansen⁶, Michael Sejer Hansen⁷, Lene Dreyer², Martin S. Jakobsen² and Merete Lund Hetland⁸, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…
Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Karine Briot¹, Thierry Schaeverbeke², Fabien Etchepare³, Philippe Gaudin⁴, Aleth Perdriger⁵, Muriel Vray⁶, Stephanie Rouanet⁷, Ghislaine Steinberg⁸ and Christian Roux¹, ¹Cochin hospital, Paris Descartes University, Paris, France, ²Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ³G.H. Pitié-Salpêtrière, Paris, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Institut Pasteur, Paris, France, ⁷Medical Department, Roche, Boulogne-Billancourt, France, ⁸Medical Department, Roche, Neuilly sur Seine, France
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…
Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Graeme Jones¹, Anthony Sebba², Denise Lepley³, Jenny Devenport⁴, Corrado Bernasconi⁵, Devi Smart⁶, Chiedzo Mpofu⁷ and Juan J. Gomez-Reino⁸, ¹Musculoskeletal, Menzies Research Institute Tasmania, Hobart, Australia, ²University of South Florida, Tampa, FL, ³Medical Affairs Immunology, Genentech, South San Francisco, CA, ⁴Genentech, South San Francisco, CA, ⁵Consultant, Basel, Switzerland, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Roche, Basel, Switzerland, ⁸Rheumatology, Hospital Clinico Universitario, Santiago, Spain
Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1 was the first trial to demonstrate…
Abstract Number: 463 • 2012 ACR/ARHP Annual Meeting
Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
Helena Forsblad-d'Elia¹, Karin Bengtsson¹, Lars-Erik Kristensen² and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: To evaluate drug survival, clinical response and predictors for drug survival for tocilizumab in patients with rheumatoid arthritis (RA) with inadequate response and/or adverse…
Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Cesar Vargas-Serafin¹, Luis Aguilar-Lozano¹, Jorge Padilla-Ibarra¹, Carlos Sandoval-Castro¹, Jose Dionisio Castillo-Ortiz¹, Jorge Morales-Torres², Claudia Hernandez² and Cesar Ramos-Remus¹, ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Rheumatology, Hospital Aranda de la Parra, Leon, Mexico
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].